• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

incardatherapeutics

PhysIQ, InCarda Therapeutics to collaborate on AFib treatment tech

August 24, 2022 By Sean Whooley

PhysIQ InCarda Therapeutics

PhysIQ announced today that it entered into a strategic collaboration with InCarda Therapeutics. Newark, California-based InCarda Therapeutics develops first-of-their-kind inhaled therapies for treating cardiovascular diseases. Get the full story at our sister site, MassDevice.

Filed Under: Business/Financial News, Cardiovascular, Clinical Trials, Drug-Device Combinations, Pharmaceuticals Tagged With: incardatherapeutics, PhysIQ

InCarda Therapeutics raises $35 million

November 8, 2019 By Sean Whooley

InCarda Therapeutics

InCarda Therapeutics — which is developing an inhaled paroxysmal atrial fibrillation drug — filed an SEC Form D confirming the sale of more than $35 million in equity. The Newark, Calif.–based drug-device combo company sold nearly $35.3 million since the first sale of the offering occurred on Oct. 20, 2017, according to yesterday’s filing. Get the full […]

Filed Under: Business/Financial News, Cardiovascular, Drug-Device Combinations, Featured, Funding Roundup Tagged With: incardatherapeutics

InCarda Therapeutics raises $42m for inhaled atrial fibrillation drug

November 8, 2018 By Sarah Faulkner

InCarda Therapeutics

InCarda Therapeutics said today that it raised $42 million in an oversubscribed Series B financing round led by Sofinnova and HealthCap. Proceeds from the round are slated to support a Phase II trial of the company’s inhaled paroxysmal atrial fibrillation drug, InRhythm. Traditional therapies for PAF include oral antiarrhythmic drugs or acute hospital procedures. InCarda’s […]

Filed Under: Cardiovascular, Drug-Device Combinations, Featured, Funding Roundup, Pharmaceuticals Tagged With: incardatherapeutics

InCarda touts inhaled flecainide as paroxysmal atrial fibrillation therapy

June 7, 2017 By Sarah Faulkner

InCarda Therapeutics

InCarda Therapeutics touted top-line data today from a Phase I study of its InRhythm inhaled flecainide as a treatment of symptomatic acute episodes of paroxysmal atrial fibrillation. InRhythm delivers flecainide via inhalation to get the drug to the heart through the lungs. Flecainide is already approved as an oral anti-arrhythmic drug for patients with PAF. […]

Filed Under: Cardiovascular, Clinical Trials, Pharmaceuticals, Respiratory Tagged With: incardatherapeutics

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS